Atria Investments Inc Grows Position in Humana Inc. (NYSE:HUM)

Atria Investments Inc boosted its holdings in Humana Inc. (NYSE:HUM) by 18.1% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 5,552 shares of the insurance provider’s stock after acquiring an additional 851 shares during the quarter. Atria Investments Inc’s holdings in Humana were worth $1,759,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of HUM. Creative Financial Designs Inc. ADV raised its position in Humana by 244.0% in the third quarter. Creative Financial Designs Inc. ADV now owns 86 shares of the insurance provider’s stock worth $27,000 after acquiring an additional 61 shares in the last quarter. CarsonAllaria Wealth Management Ltd. raised its position in Humana by 111.4% in the second quarter. CarsonAllaria Wealth Management Ltd. now owns 74 shares of the insurance provider’s stock worth $28,000 after acquiring an additional 39 shares in the last quarter. Atwood & Palmer Inc. purchased a new position in Humana in the third quarter worth $29,000. Your Advocates Ltd. LLP grew its holdings in Humana by 81.8% in the third quarter. Your Advocates Ltd. LLP now owns 100 shares of the insurance provider’s stock valued at $32,000 after purchasing an additional 45 shares during the last quarter. Finally, Hantz Financial Services Inc. acquired a new stake in Humana in the second quarter valued at $35,000. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Analyst Ratings Changes

Several analysts have weighed in on the company. Truist Financial lowered their target price on Humana from $400.00 to $260.00 and set a “hold” rating on the stock in a report on Friday, October 11th. UBS Group lowered their target price on Humana from $380.00 to $250.00 and set a “neutral” rating on the stock in a report on Friday, October 4th. KeyCorp assumed coverage on Humana in a report on Friday, October 11th. They issued a “sector weight” rating on the stock. Cantor Fitzgerald reissued a “neutral” rating and issued a $395.00 target price on shares of Humana in a report on Tuesday, October 1st. Finally, Barclays increased their price objective on Humana from $250.00 to $253.00 and gave the company an “equal weight” rating in a research note on Thursday, October 31st. Twenty equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $315.86.

Humana Stock Performance

Shares of NYSE:HUM opened at $275.67 on Friday. The company has a market cap of $33.19 billion, a P/E ratio of 24.42, a PEG ratio of 2.29 and a beta of 0.52. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.76 and a current ratio of 1.76. Humana Inc. has a one year low of $213.31 and a one year high of $527.18. The business’s 50-day simple moving average is $283.00 and its 200 day simple moving average is $331.80.

Humana (NYSE:HUM) last announced its earnings results on Wednesday, October 30th. The insurance provider reported $4.16 EPS for the quarter, beating the consensus estimate of $3.48 by $0.68. The business had revenue of $29.30 billion for the quarter, compared to the consensus estimate of $28.66 billion. Humana had a return on equity of 13.20% and a net margin of 1.18%. On average, sell-side analysts forecast that Humana Inc. will post 15.83 earnings per share for the current fiscal year.

Humana Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Tuesday, December 31st will be issued a dividend of $0.885 per share. The ex-dividend date of this dividend is Tuesday, December 31st. This represents a $3.54 annualized dividend and a dividend yield of 1.28%. Humana’s payout ratio is currently 31.36%.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.